Precision therapeutics for early onset epilepsy: Allele-selective antisense oligonucleotides for SCN2A-related epilepsy

Olivia Kim-McManus · 2026

Read Precision therapeutics for early onset epilepsy: Allele-selective antisense oligonucleotides for SCN2A-related epilepsy by Olivia Kim-McManus (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579270.txt.

Description

Olivia Kim-McManus reviews precision therapy for epilepsy caused by the SCN2A gene, where seizures begin at birth and resist standard drugs. SCN2A is among the most common single-gene epilepsies, and its variants can overexcite the sodium channel it builds. Silencing just the faulty copy is the elegant idea behind allele-selective antisense therapy.

Short synthetic strands, antisense oligonucleotides, can be tuned to the mutant allele while sparing the healthy one. The review weighs why genotype matters so much here, since variants differ in whether they boost or blunt the channel. For families facing static development despite best drugs, targeted genetic treatment offers a rational new hope.

Catalog record

CREATOROlivia Kim-McManus
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE6 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13579270

Browse the full library · About the Tower of Babel